There’s no approved vaccine for the Bundibugyo strain — and today, for the first time this week, that fact is the story, not a footnote. This is Ebola Watch. And honestly, Cera — I came in today wanting to know what actually stops this if there’s no shot. Then we’re in the right place. We’ve got two new Africa CDC guidance documents, a WHO Europe preparedness page going live, and a fatality number that needs careful handling. Careful handling — meaning the scary one. Let’s start there. A piece in The Conversation, carried by TimesLIVE, puts the Bundibugyo strain’s fatality rate at 30 to 50 percent. But the case-fatality rate WHO is reporting for this actual outbreak is 17.4 percent. Those are different measurements, so listeners shouldn’t average them. Okay, but 30 to 50 versus 17 — that’s a huge spread. Which number am I supposed to take with me? Neither one, by itself. The 30-to-50 is what the strain has done historically — different settings, different counting, often with less supportive care. The 17.4 reflects this outbreak’s treatment and how completely cases are being found. That gap tells us something. And the part that lands for a traveler — the CDC restriction tells you where not to fly. The vaccine story tells you there’s no safety net if tracing misses one person at a gate. Which retroactively makes MSF look smart for setting access terms before there’s anything to access. I’ll give them that. Setting the price of a ticket before the train’s been built. This week I was skeptical. Today I’m not. Now the part I want to chew on — Africa CDC put out interim guidance pushing back on blanket travel restrictions. Washington’s CDC already restricted DRC, Uganda, South Sudan. Those are two agencies running different playbooks. And it’s the first time a major African health body has put that disagreement in formal writing. It connects straight to the Kinshasa-Kampala border tension — except now it’s not just WHO making the case in diplomatic language. So when official agencies disagree, I don’t want it smoothed over. Is Africa CDC saying the restrictions are useless, or saying do them differently? Do them differently — targeted, evidence-based, not a wall. The second document is their Points of Entry surveillance guidance, and it shows where the burden is shifting. Right, because contact tracing inside the outbreak zone is still stuck at 45 percent against a 90 percent threshold. So the gap is getting routed to the borders instead of closed. That’s today’s shift. Border surveillance is having to cover work that in-zone tracing can’t. Africa CDC is basically designing around the shortfall rather than waiting on it. Then tell me what “enhanced surveillance at a point of entry” actually is. Which airports, which crossings, and what’s a screener checking for if there’s no rapid approved test for this strain? Mostly symptom and travel-history screening, temperature checks, exposure questions — the same blunt tools, because lab confirmation can’t happen at the gate. That’s the limitation the guidance is quietly working within. So a screener is asking where you’ve been and taking your temperature. For a virus with a 30-to-50 percent strain fatality and no vaccine. That’s the safety net. It’s a net with wide gaps, honestly. And that’s why WHO Europe’s new preparedness page matters — it names this as a Bundibugyo outbreak spanning both DRC and Uganda at once. Europe formally naming both countries — is that them prepping field supply lines, or just airport screening on their end? It’s unclear from the page itself — and that distinction matters. Importation screening for Europe is one thing. Activating European logistics to get protective gear into Ituri is another, and far more useful on the ground. Because the last-mile supply problem for PPE in Ituri hasn’t gone anywhere. A preparedness page in Copenhagen doesn’t move gloves to Butembo. No, it doesn’t. So here’s where the week lands: no vaccine, no approved treatment for this strain, tracing at half the threshold, and the agencies disagreeing on the bluntest tool we’ve got. Every tool people assume exists in an outbreak — the shot, the cure, the tracing — all missing at the same time. I’m not catastrophizing; I’m just reading the list. It’s why the borders and the European page and the surveillance protocols all feel so urgent — they’re standing in for tools that aren’t there yet. Stay with us. We’ll keep you precise, not panicked. The World Health Organization has the details on this one. The WHO situation page now frames this as one outbreak running in both DRC and Uganda at once — Bundibugyo virus, dual-country scope, stated plainly. That’s the frame everything else this week has been built around. And it’s the page that carries the PHEIC — the WHO’s top alarm level, the one the Emergency Committee reportedly waited three meetings to call. Cera, walk me through what’s actually changed on it since the declaration. The case-fatality figure WHO is citing for this outbreak sits at 17.4 percent. Hold that against the 30-to-50 percent people will see attached to Bundibugyo as a strain — they’re not measuring the same thing. Right, and a listener’s going to average them and land at thirty-something. Why the gap? Because the 17.4 reflects this outbreak — the supportive care that reached patients, which cases actually got counted. The strain number is what Bundibugyo can do in a harder context. One is a snapshot of now; the other is the historical warning sign. Joël Lumbala, writing in World Health Organization:
On 17 May 2026, WHO’s Director-General determined that Ebola disease caused by Bundibugyo virus (BDBV) in DRC and Uganda constitutes a public health emergency of international concern (PHEIC), as defined in the provisions of the International Health Regulations (2005) (IHR).
WHO’s European regional office has put up a preparedness page — and the key detail is the framing. It names this as a Bundibugyo outbreak across DRC and Uganda at the same time, the first time the European office has formally written that dual-country scope into a preparedness document. Okay, but preparedness for what? Europe isn’t seeing cases. Is this about protecting people in Lyon, or about screening someone who flies in from Entebbe? Read it closely and it’s about importation and coordination. The risk to people living in the European Region stays low — what’s escalating is the institutional machinery, not the threat at the gate. And the timeline tells you how fast that machinery moved. After DRC and Uganda raised the alarm, WHO declared the emergency on May 17, Africa CDC followed on May 18, and the IHR committee convened on May 19. Here’s what Africa Centres for Disease Control and Prevention is reporting. So Africa CDC just published points-of-entry surveillance guidelines specifically for Bundibugyo. Cera — in plain geography, what is a screener at a crossing actually checking for here? Temperature, symptom history, travel origin in the affected zones — the standard entry-screening kit. The hard part is there’s no rapid approved test for this strain, so a screener is working off symptoms and questions, not a swab that confirms anything. Which means someone incubating and asymptomatic walks straight through. So the wall is really more like a speed bump. It’s a net with wide holes, yes. But read it against the 45 percent contact-tracing coverage inside the outbreak zone — the field can only trace half the chains. Africa CDC is pushing more surveillance to the borders because the numbers inside the zone aren’t catching up. So the border becomes the backstop for tracing that isn’t happening. Reassuring. I’d put it as honest rather than reassuring. And note who’s issuing it — this is the continent’s own health body building the surveillance system, not an importing country walling itself off. That distinction matters for what comes next in this rundown. Here’s what Africa Centres for Disease Control and Prevention is reporting. Okay, here’s the part nobody’s said out loud yet — Africa CDC just published interim guidance basically telling governments how not to slap blanket travel restrictions on this outbreak. And Washington’s CDC already did exactly that across DRC, Uganda, and South Sudan. That’s the part to sit with. This is the first time the continent’s own health body has put its disagreement into formal interim guidance, not a press quote. And it ties right back to the Uganda-DRC border fight — the closure at Mpondwe, the Kinshasa-Kampala tension. Now there’s an institutional voice saying a sealed border isn’t the disease-control win it looks like. So you’ve got two playbooks running at the same checkpoints. Africa CDC says don’t wall it off, do enhanced surveillance — and the U.S. just walls it off. Those don’t reconcile. Here's TimesLIVE:
The ongoing Ebola virus outbreak in the Democratic Republic of the Congo (DRC) and Uganda has now killed 61 people, with 359 confirmed cases. The Bundibugyo strain of the virus has a fatality rate of between 30% and 50%, and there is currently no vaccine approved for it. Two scientists at the University of Oxford, Teresa Lambe and Rebecca Makinson, are part of the group who are working to develop one.
Here’s the number that changes how the whole week reads: the Bundibugyo strain carries a 30 to 50 percent fatality rate, and as of this report, 61 deaths among 359 confirmed cases. No approved vaccine exists for it. And I want to be careful, because that 30-to-50 isn’t the same thing as the 17.4 percent case-fatality we’ve been citing for this outbreak. The outbreak number reflects supportive care and whether mild cases are even being counted. The strain number is what the virus does when nothing softens it. So put those two facts in one sentence for me: the CDC restriction tells a traveler where not to fly, and this tells them there’s no safety net if tracing misses someone who’s already on the plane. No vaccine, no approved treatment, tracing at 45 percent. Every tool people assume exists in an outbreak — all absent at once. Right. And notice what’s new — Oxford just got CEPI funding, with Teresa Lambe and Rebecca Makinson explaining the work. That makes MSF’s earlier access push look timely; they were setting terms before the tool existed because access can’t be an afterthought. Though here’s my snag — Muyembe said this response has to run through Congo’s own health system. A vaccine push routed through Oxford labs isn’t exactly that. How do those two stories hold together? If you come to Ebola Watch for clear daily risk updates, try Iran War Daily: a daily foreign-affairs briefing on the U.S.-Israel-Iran war, from strikes and ceasefire talks to oil markets and spillover. Find it wherever you listen to podcasts.
We’ve put links to all of today’s stories in the show notes, so if one caught your attention, you can follow it there and read more. That’s Ebola Watch for today. This is a Lantern Podcast.